Protein aggregation mediates stoichiometry of protein complexes in aneuploid cells

Authors: Christopher M. Brennan¹,²,³, Laura Pontano Vaites⁴,⁸, Jonathan N. Wells⁵,⁸, Stefano Santaguida¹,²,³,⁷, Joao A. Paulo⁴, Zuzana Storchova⁶, J. Wade Harper⁴, Joseph A. Marsh⁵, and Angelika Amon¹,²,³,*

Affiliations:

¹David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
²Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
³Paul F. Glenn Center for Biology of Aging Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
⁴Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA
⁵MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, Western General Hospital, University of Edinburgh, Edinburgh EH4 2XU, UK
⁶TU Kaiserslautern, 67663 Kaiserslautern, Germany
⁷Department of Experimental Oncology, European Institute of Oncology, IEO, Via Adamello 16, 20139 Milan, Italy
⁸These authors contributed equally to this work

*Correspondence: angelika@mit.edu
Abstract (121 words)

Aneuploidy, a condition characterized by chromosome gains and losses, causes reduced fitness and numerous cellular stresses, including increased protein aggregation. Here, we identify protein complex stoichiometry imbalances as a major cause of protein aggregation in aneuploid cells. Subunits of protein complexes encoded on excess chromosomes aggregate in aneuploid cells, which is suppressed when expression of other subunits is coordinately altered. We further show that excess subunits are either degraded or aggregate and that protein aggregation is nearly as effective as protein degradation at lowering levels of excess proteins. Our study explains why proteotoxic stress is a universal feature of the aneuploid state and reveals protein aggregation as a form of dosage compensation to cope with disproportionate expression of protein complex subunits.
Introduction
Eukaryotes have a problem - subunits of protein complexes are not encoded in operons. Although eukaryotes have evolved to coordinate expression of subunits of the same complex (Li et al. 2014; Taggart and Li 2018), changes in gene dosage of a subset of subunits of a protein complex, transient gene copy number imbalances during DNA replication, or fluctuations in gene expression can disrupt this coordinate expression, leading to the production of complex subunits that lack their binding partners. These orphan subunits have the potential to mis-fold and cause proteotoxic stress. How eukaryotic cells deal with stoichiometric imbalances is a fundamental, yet largely unexplored question.

Aneuploidy represents an especially dramatic case of gene dosage alteration because changes in autosome copy number generally lead to a corresponding change in the levels of RNAs and proteins produced by genes located on aneuploid chromosomes (Torres et al. 2010; Pavelka et al. 2010; Dephoure et al. 2014). Not surprisingly these dramatic alterations in cellular protein composition significantly impact cellular physiology, causing cell proliferation defects, metabolic alterations, and oxidative stress (reviewed in (Santaguida and Amon 2015)). Protein homeostasis defects are especially prevalent in aneuploid cells. In budding yeast, many different aneuploidies harbor more protein aggregates, display decreased chaperone activity, and exhibit sensitivity to conditions that interfere with proteasomal degradation (Oromendia et al. 2012; Torres et al. 2007). In mammals, aneuploidy also disrupts protein homeostasis leading to altered autophagy, abnormal protein folding, and accumulation of protein aggregates (Donnelly and Storchová 2014; Santaguida et al. 2015; Stingele et al. 2012; Tang et al. 2011). Why protein aggregation is so wide-spread in aneuploid cell lines was not understood.

We previously generated a series of haploid yeast strains each harboring an extra copy of one of the 16 yeast chromosomes (henceforth disomes; (Torres et al. 2007)). Analysis of the localization of Hsp104, a disaggregase that associates with protein aggregates (Liu et al. 2010), showed that gain of any of the 16 yeast chromosomes causes an increase in the number of cells harboring Hsp104 foci, providing evidence for increased protein aggregation (Oromendia et al. 2012). Here we determine the molecular basis of this phenotype. We find that subunits of protein complexes encoded on excess chromosomes aggregate in aneuploid cells. Our analyses also provide insights into how cells respond to protein stoichiometry imbalances. Protein aggregation can quantitatively deplete excess protein from the cytosol. We conclude that protein aggregation commonly performs functional dosage compensation.

RESULTS
Identification of proteins that aggregate in aneuploid yeast cells
Previous studies of proteotoxic stress in aneuploidy had shown that cells with defined chromosome gains or randomly generated, unknown karyotypes harbored increased levels of protein aggregates (Oromendia et al. 2012; Santaguida et al. 2015; Stingele et al. 2012). To gain
insight into why protein aggregation is so common in aneuploid cells, we determined the composition of protein aggregates in disomic yeast strains. We isolated protein aggregates from disomic yeasts by a stringent differential centrifugation method (Koplin et al. 2010). Hsp104 was enriched in aggregate fractions (Fig. 1A), however we note that aggregates isolated in this manner may not contain all Hsp104 decorated aggregates, and also may contain aggregates not recognized by Hsp104. Analysis of protein aggregates by SDS-PAGE revealed that protein aggregation is increased in aneuploid cells. Cells that mis-segregate chromosomes at a high frequency because they carry a temperature sensitive allele in the kinetochore component encoding gene *NDC10* harbored high levels of protein aggregates (Fig. 1B). Increased amounts of aggregated proteins were also observed in haploid cells disomic for chromosome V (Fig. 1B).

Having established that aneuploidy causes an increase in protein aggregates that can be isolated by differential centrifugation, we used SILAC mass spectrometry (ms) to identify proteins that preferentially aggregate in 12 different disomic yeast strains (Ong et al. 2002; Shevchenko et al. 2006) (Supplemental Fig. S1A; Fig. 1C; Supplemental Data S1). Reproducibility was high between individual experiments: 70% of proteins were identified in repeats of individual experiments (Supplemental Fig. S1B, C). Although biological replicates were well correlated, the mean of the SILAC ratios for all proteins combined in aggregates varied between replicates of the same disome (e.g. for disome II, the means were 0.59, 0.69, and 0.30). To account for this variability and to be able to conduct analyses on the aggregate data set as a whole, we mean centered all experiments such that the mean relative enrichment was equal across experiments (Fig. 1C). Each experiment was mean-centered to 0 by subtracting the mean of all SILAC ratios in that experiment from all data points. To return the normalized values to a baseline that more closely resembles the increase in protein aggregation in disomic strains observed in the raw data, a constant (log2 0.27) was added to all normalized data points. This constant is the mean log2 ratio of all euploid encoded proteins in the dataset prior to normalization. Of note, we also identified proteins that were enriched in aggregates isolated from euploid strains compared to disome strains. However, in triplicate experiments for disome II, only 4 proteins (1.4%) were enriched more than two-fold in aggregates from euploid cells and their enrichment across replicate experiments was highly variable (Supplemental Fig. S1D, E).

Which proteins aggregate in disomic yeast strains? The similar banding patterns of WT and aneuploid aggregates on SDS-PAGE gels (Fig. 1B) indicated that aggregates were composed of the same proteins, but that they aggregate more in aneuploid strains than euploid strains.

Comparison of the banding pattern of protein aggregates on SDS-PAGE with the banding pattern of purified ribosomes further suggested that protein aggregates of both euploid and disomic yeast strains were enriched for ribosomes (Supplemental Fig. S2A). To estimate the contribution of ribosomes to protein aggregates in disomic yeast strains we first determined the abundance of proteins in aggregates in each strain relative to its euploid reference by summing the raw total intensity of all heavy-labeled peptides and all light-labeled peptides and then calculating a ratio.
of the two (Supplemental Fig. S2B). Nine out twelve disomic strains contained more aggregated protein than euploid controls by this estimate. We then calculated the signal of each ribosomal protein as a percentage of the total signal for all aggregated proteins and determined that 75% of aggregated proteins were ribosomal proteins. Interestingly, the disomic strains with fewer ribosomes aggregating were the same strains that showed lower levels of total aggregate burden (compare Supplemental Fig. S2B and C) confirming that ribosomes make up the majority of aggregating proteins in disomic yeast strains. Two lines of evidence indicate that it is assembled ribosomes rather than individual subunits that accumulate in aggregates. First, almost all excess ribosomal subunits are quantitatively degraded in disomic yeast strains (Dephoure et al. 2014). Second, the coomassie staining pattern of protein aggregates on SDS-PAGE resembles the pattern of purified intact ribosomes (Supplemental Fig. S2A). We conclude that ribosomes are abundant in aggregates purified by our method in both euploid and aneuploid yeast strains, but that they aggregate more in disomes.

To determine which proteins other than ribosomes are found in aggregates purified by our differential centrifugation method, we assessed the presence of known phase-separated structures such as P bodies, stress granules, or nucleoli in purified aggregates (Banani et al. 2017) using the annotations by (Jain et al. 2016). P body proteins were significantly underrepresented in aggregates compared to total lysates (Supplemental Fig. S2D). We also identified fewer stress granule proteins and nucleolar proteins in aggregates compared to total lysates, however this difference was not significant (Supplemental Fig. S2D). We conclude that components of phase-separated structures are not significantly enriched in our aggregate preparations.

Next, we conducted an unbiased Gene Ontology (GO) analysis (Supplemental Fig. S2E) to determine which proteins were in fact enriched in aggregates isolated from aneuploid strains. Macromolecular complex was the GO term most significantly associated with proteins in aggregates, suggesting that complex subunits may be predisposed to aggregation. Ribosomes were the second most significant GO term, confirming our observation that the organelle is enriched in our aggregate preparation. The term “non-membrane bound organelle” (fourth most significant GO term) includes ribosomes which likely drives the significance of this GO term. The third most significant GO term was “cell”, which we interpret to mean that all GO terms with p-values larger than this generic GO term, which includes the GO terms mitochondrion, nucleolus, and membrane, are not likely to be meaningful. This conclusion is supported by our observation that proteins known to be components of the nucleolus are not enriched in aggregates isolated from disomic yeast strains.

Next, we examined the physical and chemical properties of aggregating proteins. For this analysis, we compared aggregating proteins to the whole yeast proteome and to proteins identified in lysates from which the aggregates were purified. Proteins in both aggregates and total lysates had more disordered regions than the whole proteome (Supplemental Fig. S3A).
Hydrophobicity did not affect aggregation propensity (Supplemental Fig. S3B). Amino acid composition appeared to affect protein aggregation in aneuploid yeast strains. Aggregated proteins were more basic and contained slightly more aromatic residues than proteins identified in lysates (Supplemental Fig. S3C-E). Whether these features influence aggregation propensity remains to be determined. Based on our knowledge of the effects of aneuploidy on cell physiology and the fact that “macromolecular complex” was the most significant GO term describing proteins that aggregate in disomic yeast strains, we can, however, envision two classes of proteins that aggregate in disomic yeast strains:

1. Proteins that rely extensively on protein folding pathways to achieve their native conformation. Such proteins could aggregate because protein quality control is compromised in aneuploid yeast strains (Oromendia et al. 2012; Torres et al. 2010). Aggregation of these proteins ought to be independent of the identity of the aneuploid chromosomes and should occur in multiple different disomic yeast strains.

2. Proteins encoded by the duplicated chromosome. Such proteins could aggregate because they are in excess.

We first focused on proteins in class 1.

Proteins that aggregate in multiple disomes also aggregate in cells with compromised protein quality control

Aneuploid cells experience proteotoxic stress (Oromendia et al. 2012; Santaguida et al. 2015; Stingele et al. 2012; Tang et al. 2011). Proteins that rely extensively on protein folding pathways to achieve their native conformation could thus aggregate in aneuploid cells more so than in euploid cells. To identify proteins that exhibit an increased aggregation due to the aneuploid state, we identified proteins that (1) were encoded on euploid chromosomes, (2) aggregated in at least 3 different disomic yeast strains, and (3) had an average enrichment of at least 2.4-fold \([\log_2 1.27]\) in disomic aggregates. We arrived at this cutoff for enrichment of proteins in disome aggregates using a false discovery rate of 5\% (see Materials and Methods). This analysis identified 22 proteins (Fig. 1D; Supplemental Data S2).

If proteins aggregate in multiple different disomic strains because proteostasis is compromised they should also aggregate in euploid cells in which protein quality control pathways are inhibited. To test this, we analyzed protein aggregates of cells harboring a temperature sensitive mutation in the proteasome subunit encoding gene \(RPN6\) (Isono et al. 2005) and of cells treated with the Hsp90 inhibitor radicicol (Supplemental Fig. S4; Supplemental Data S2). For the 22 proteins identified as aggregating in multiple disomic strains, we obtained quantitative information for 14 in aggregates of either \(rpn6-1\) or radicicol-treated cells, or both. Of these, 13 (94\%) were enriched 2.4-fold \([\log_2 1.27]\) in aggregates of \(rpn6-1\) or radicicol-treated cells, or both (Fig. 1E, p<0.001, hypergeometric cumulative distribution function). We conclude that
proteostasis deficiency causes protein aggregation in aneuploid cells regardless of whether gene copy number is altered or not.

**Duplicated proteins are highly enriched in aneuploid aggregates**

We next examined proteins encoded on disomic chromosomes. These proteins were indeed significantly enriched in aggregates isolated from their respective disomic strain (Fig. 1C; red dots). To determine the number of proteins that aggregate because they are produced from two rather than one gene copy, we used a cutoff of 2.4-fold \( \log_2 1.27 \) (based on a 5% FDR, described above) to define aggregate enrichment. We identified 437 proteins that were enriched in aggregates in a disome-specific manner (Supplemental Data S1; Fig. 1F). For example, chromosome II encodes for 13% of the yeast proteome when duplicated, yet 36% of proteins that aggregate in strains disomic for chromosome II are encoded on chromosome II. Similarly dramatic results are observed in all disomic strains (Fig. 1F). We further note that this enrichment of disome-encoded proteins in aggregates underestimates proteins that aggregate because they are produced in excess. Proteins that fall below an established signal to noise ratio in either the heavy or light channel cannot be included because a SILAC ratio cannot be calculated. To mitigate this limitation, we examined proteins that did not pass the signal to noise threshold in one channel, but had a signal to noise ratio (S:N) of at least twice the threshold in the other channel (see Materials and Methods). This identified an additional 320 proteins that were quantified only in disome aggregates compared to just 72 that were only identified in aggregates of the euploid control strain (Supplemental Data S1). Importantly, 92 of the proteins quantified only in aggregates of disomic strains were encoded on the disomic chromosome, as opposed to just 2 that were quantified only in aggregates of euploid strains (Fig. 1G). We conclude that at least 529 proteins (437 proteins identified as enriched in disomes compared to wild-type aggregates + 92 identified only in disome aggregates) aggregate when their gene copy number is increased by two-fold.

**Increasing gene copy number by one causes protein aggregation in human cells**

Is protein aggregation a feature of aneuploidy that is conserved across eukaryotes? To address this question, we analyzed protein aggregation in near diploid human RPE-1 cells and two derivatives that were trisomic for chromosomes 12 or 21 (Stingele et al. 2012). As in yeast, proteins most enriched in aggregates were encoded on the trisomic chromosome. Within the 10\textsuperscript{th} percentile of proteins most enriched in trisomy 12 aggregates, 16.2\% of proteins were encoded by chromosome 12 (Fig. 2A, B; Supplemental Data S3). This enrichment was highly significant (Fisher’s exact test \( p<0.0001 \)). In contrast, proteins encoded by other chromosomes had no significant enrichment, with the exception of proteins encoded by chromosome 4 which were slightly depleted (Fisher’s exact test \( p=0.0297 \)). We conclude that chromosome 12-encoded proteins are enriched in aggregates of trisomy 12 cells.
Enrichment of chromosome 21-encoded proteins was not evident in aggregates purified from trisomy 21 cell lines (Fig. 2A, C; Supplemental Data S3) most likely due to the fact that chromosome 21 is the gene poorest chromosome in humans. To increase protein aggregation in trisomy 21 cells, we prevented protein degradation by inhibiting the proteasome and lysosomal degradation with MG-132 and chloroquine, respectively. In this experiment, we observed that within the 10th percentile of proteins most enriched in trisomy 21 aggregates, 3.2% were encoded by chromosome 21. Overall, proteins encoded on chromosome 21 represent only 1% of proteins in aggregates (Fig. 2D, E; Supplemental Data S3). This enrichment was highly significant (Fisher’s exact test p=0.0005). In contrast, proteins encoded on other chromosomes did not show significant enrichment. Among the chromosome 21 encoded proteins enriched in aggregates were two proteins known to contribute to disease phenotypes in Trisomy 21 - DOPEY2, a protein implicated in causing mental retardation (Rachidi et al. 2005) and APP, the precursor of the Alzheimer’s disease-associated amyloid-β. We conclude that aggregation of proteins encoded on excess chromosomes is also a feature of aneuploidy in humans. We note that the enrichment of proteins encoded on excess chromosomes is less apparent in trisomic human cells than in disomic yeast cells. This is to be expected. Gain of a copy of a chromosome in a diploid cell causes fewer protein imbalances than gain of a chromosome in a haploid cell.

Stoichiometric imbalance of protein complexes can cause protein aggregation

We next examined the mechanism whereby altering gene copy number causes protein aggregation in aneuploid cells. Protein complex analysis using the annotation by (Pu et al. 2009) showed that 44.2% of the 529 proteins, that aggregated in disomic yeast strains when encoded on an excess chromosome, were subunits of protein complexes (Fig. 3A). By comparison, only 29.2% of proteins encoded by euploid chromosomes that were enriched in aggregates, were subunits of protein complexes (Fig. 3A).

We hypothesized that the enrichment of duplicated protein complex subunits in disome aggregates was due to protein complex subunits requiring binding to other subunits to acquire their native state. This hypothesis predicts that when gene copy number of the other complex subunits is altered in accordance with expression of the subunit produced in excess, aggregation should be prevented. We tested this prediction by studying the eIF2 complex, which is required for translation initiation and composed of three subunits. The eIF2 γ-subunit, Gcd11, is encoded on chromosome V (Fig. 3B). Gcd11 was found in aggregates isolated from yeast strains disomic for this chromosome but returned to euploid levels in aggregates from disome V strains in which one copy of GCD11 was deleted (Fig. 3C-E). In fact, a single extra copy of GCD11 in an otherwise euploid strain was sufficient to cause Gcd11 aggregation (Fig. 3C-E). Thus, increased gene dosage of GCD11 is necessary and sufficient to cause aggregation of the protein. It is worth noting that Gcd11 aggregated less when expressed in excess by itself than when overexpressed due to an extra copy of chromosome V. This observation suggests that proteotoxic stress caused by disomy of chromosome V exaggerates aggregation of Gcd11.
To test whether aggregation of Gcd11 in disome V strains can be prevented by doubling the gene copy number of the eIF2 α-subunit encoding gene SUI2 and the eIF2 β-subunit encoding gene SUI3, we introduced a centromeric plasmid carrying both genes under their native promoters into disome V strains. Expression of SUI2 and SUI3 dramatically reduced Gcd11 aggregation in disome V cells (Fig. 3F-H). We note that expression of SUI2 and SUI3 also increased Gcd11 levels in lysates (Fig. 3F). A pool of Gcd11 is degraded when expressed in excess (Dephoure et al. 2014). Increased expression of Sui2 and Sui3 likely also protects Gcd11 from degradation. We conclude that stoichiometric imbalance of protein complexes can cause protein aggregation in aneuploid cells.

Excess proteins either aggregate or are degraded

Previous studies showed that many proteins that function in protein complexes are degraded when in excess in aneuploid cells, restoring their levels to euploid or near euploid levels (Dephoure et al. 2014; Gonçalves et al. 2017; Ori et al. 2016). We observed that many proteins aggregate when in excess. An important question regarding these two observations is whether excess subunits are down-regulated by both mechanisms or whether they are neutralized by one or the other. To distinguish between these possibilities, we analyzed protein degradation and aggregation propensity for all disome-encoded proteins identified in our protein aggregate analysis and the protein degradation analysis of Dephoure et al. (2014). Note that both data sets were created with the same strains. Analysis of the relative abundance of proteins encoded on disomic chromosomes confirmed that the two data sets were indeed similar to each other, despite slight differences in growth conditions (Supplemental Fig. S5).

We first asked whether relative abundance of a protein in total lysates correlates with protein aggregation - or in other words, is a protein more likely to aggregate when its levels in total lysate are higher than in a euploid strain? We indeed observed a weak but significant correlation (Fig. 4A). This observation indicates that proteins that are dosage compensated by protein degradation are less likely to be found in aggregates. Because excess cytoplasmic ribosomal subunits are almost exclusively degraded (Dephoure et al. 2014), we also asked whether the correlation was driven by ribosomal proteins. Removing cytoplasmic ribosomal proteins from the data set weakened the correlation between abundance of proteins in extracts and their propensity to aggregate, but it was still significant (Supplemental Fig. S6A).

To further assess whether protein aggregation and degradation are mutually exclusive we analyzed the data using cutoffs previously set to define a protein to aggregate or to be degraded when in excess. Dephoure et al. (2014) defined a disome-encoded protein as degraded when its abundance in extracts relative to a euploid reference was 1.52 [log2 0.6] instead of the expected 2 [log2 1]. We defined any disome-encoded protein aggregated when it was found enriched 2.4-fold [log2 1.27] in aggregates (Fig. 1). Based on these criteria, only 100/983 (10%) disomic
proteins were considered both to aggregate and to be degraded when in excess. This is evident by the fact that the upper left quadrant in the graph in Fig. 4A is underpopulated (p= 0.0045; Fisher’s exact test). This mutual exclusive behavior of disome encoded proteins was not driven by ribosomal proteins because we observed the same under population of the left upper quadrant when we removed ribosomal proteins (Supplemental Fig. S6A). When we restricted our analysis to subunits of protein complexes only 67 out of 424 (16%) proteins were both enriched in disome aggregates and degraded when in excess (p= 0.0012; Fisher’s exact test; Fig. 4B), although we note that this observed lack of overlap between aggregation and degradation was, to a significant extent, driven by ribosomal proteins (Supplemental Fig. S6B).

Another way to assess whether disome-encoded proteins aggregate or are degraded but not both, is to ask: Are disome-encoded proteins that are highly enriched in aggregates, present in total lysates at the 2x level expected for disome-encoded proteins or are their levels lower? We found that disome-encoded proteins that are enriched in aggregates, are present at levels close to the expected level of two-fold indicating that they are not degraded (Fig. 4C). In contrast, levels of proteins that were detected in aggregates but not enriched in aggregates were lower in total lysates (Fig. 4C). Removal of ribosomal subunits from the analysis did not alter this conclusion (Supplemental Fig. S6C). The results were even more striking when we focused our analysis on disome-encoded proteins that are part of protein complexes (Fig. 4D, S3D). We conclude that proteins, when present in excess, have a preferred fate of either degradation or aggregation.

**Protein complex subunits that aggregate when in excess have lower turnover rates than degraded subunits**

What determines whether excess protein complex subunits aggregate or are degraded?

Computational analyses revealed that both classes of subunits harbor large protein-protein interfaces within their complexes compared to proteins that neither aggregate nor are degraded (Fig. 5A; Supplemental Data S4; (Marsh et al. 2013)). This is consistent with earlier work in mammalian cells, demonstrating that protein complex subunits with larger interfaces tend to be unstable and rapidly degraded when not bound to their partners (McShane et al. 2016). If overexpressed relative to other components of the complex, these large interfaces could facilitate inappropriate protein-protein interactions, leading to aggregation instead of degradation (Levy et al. 2012).

Given that excess protein complex subunits that are degraded and that aggregate both harbor large protein binding interfaces, we hypothesized that their fate could be determined by differences in recognition by the ubiquitin/proteasome or lysosomal degradation systems. Previous work showed that degradation of proteins that are encoded on a disomic chromosome, can be prevented by treating disomic cells with the proteasome inhibitor MG-132 and the lysosomal-degradation inhibitor chloroquine ((Dephoure et al. 2014), Fig. 5B; right part of the graph). Importantly, we find that preventing protein degradation did not affect overall levels of
individual proteins that aggregate (Fig. 5B, left part of the graph) and average levels of all proteins that aggregate (Fig. 5C; Supplemental Data S4). Therefore, proteins found in aggregates generally have low turnover rates.

To further assess whether protein stability determines whether or not a protein aggregates, we analyzed the effects of proteasome inhibition on the fate of proteins that are normally degraded when in excess. Partial inhibition of the proteasome using a temperature sensitive rpn6-1 mutant grown at the semi-permissive temperature (30°C) caused a general increase in protein aggregation for all proteins in disome II cells (Fig. 5D; Supplemental Data S4). 67 disomic proteins are normally degraded in cells disomic for chromosome II (Dephoure et al. 2014). We identified 31 of these in our analysis. 11 out of 31 (35.5%) aggregated in disome II cells with a functional proteasome. In disome II rpn6-1 cells we identified 41 out of these 67 proteins. 21 (51.2%) of these were enriched in aggregates (Fig. 5E). We then asked whether the 67 proteins that were typically degraded when duplicated in disome II cells were enriched in aggregates when proteasome function is compromised. In cells with normal proteasome function, the 67 proteins had a mean enrichment of 1.9 [log2 0.92] in disome II aggregates. In disome II rpn6-1 cells, their mean enrichment increased to 4.0 [log2 2.0] indicating that many of these usually degraded proteins are now deposited in protein aggregates (Fig. 5F).

We next determined the effects of protein stability on the choice between degradation or aggregation by analyzing the origin recognition complex (ORC) in which some subunits are degraded when in excess while others are not (Dephoure et al. 2014). The origin recognition complex (ORC) is a six subunit complex essential for the initiation of DNA replication (Bell et al. 1993). All six subunits are encoded on different chromosomes in yeast.

Orc2 levels are mostly attenuated (reduced to 1.1 [log2 0.16] relative to WT) by degradation when the ORC2 gene is present in two copies instead of one ((Dephoure et al. 2014), Fig. 5G). In contrast, Orc5 is not attenuated (present at 1.8 [log2 0.88] relative to WT) by degradation but is highly enriched in aggregates when encoded by two gene copies (Fig. 5G, H). To mimic stoichiometric imbalance, we transiently overexpressed Orc2 and Orc5 individually from the galactose-inducible GAL1-10 promoter. Half-life measurements showed that overproduced Orc5 was twice as stable as overproduced Orc2 (Fig. 5I, J). We conclude that the stability of a protein can determine whether it aggregates or is degraded when produced in excess. Our data further indicate that surprisingly subtle half-life differences can determine a protein’s dosage compensation fate. What minimal half-life is required for a protein to be eliminated by degradation when in excess remains to be determined.

**Dosage compensation by protein aggregation**

Degradation of excess subunits of protein complexes serves as a form of dosage compensation (Dephoure et al. 2014). Can protein aggregation serve the same purpose by sequestering excess
subunits in an inaccessible aggregate compartment? To address this question, we quantified the relative abundance of proteins that remained in the soluble fraction following aggregate isolation in yeast strains disomic for chromosome II or XII and compared it to their abundance in extracts prior to aggregate removal (henceforth total lysate) (Supplemental Fig. S1A). We observed a small but nevertheless significant difference in relative abundance of proteins encoded on euploid chromosomes between soluble fractions and total lysates (Fig. 6A, B; Supplemental Data S5), which is consistent with the observation that proteins encoded on euploid chromosomes are also found enriched in aggregates isolated from aneuploid cells (Fig. 1C). Depletion of proteins encoded on disomic chromosomes from the soluble fraction was, however, much more dramatic.

Their mean relative abundance in the soluble fraction was noticeably decreased to 1.59-fold [log2 0.67] compared to 1.66-fold [log2 0.74] in total lysates for disome II and 1.69-fold [log2 0.76] compared to 1.77-fold [log2 0.82] for disome XII (Fig. 6A, B; Supplemental Data S5).

The decrease of disome-encoded proteins in the soluble fraction could be due to many proteins experiencing small amounts of aggregation or a few proteins aggregating to a large degree. To distinguish between these possibilities, we first calculated the change in levels for each protein by subtracting protein levels in the soluble fraction from those in the total lysate. We then pooled the data from the disome II and disome XII analysis and generated two bins – proteins that were encoded on disomic chromosomes and proteins encoded on euploid chromosomes. As expected, the changes in levels of the 6495 proteins encoded by euploid chromosomes were evenly distributed (Fig. 6C; gray bars); changes in levels of the 575 proteins encoded by disomic chromosomes were not. Both the mean and skew significantly deviated from the expected distribution (Fig. 6C). 147 of the 575 (26%) disome-encoded proteins were depleted by 1.15-fold [log2 0.2] in the soluble fraction compared to total lysate (Fig. 6E), 12% by 1.32-fold [log2 0.4]. Full attenuation, as defined as a 1.74-fold [log2 0.8] decrease occurred for 3% of proteins (Fig. 6E). This indicates that reduction in protein levels for duplicated proteins in the soluble fraction is largely due to many proteins decreasing by a small degree. However, full attenuation by aggregation also occurs.

How does dosage compensation by aggregation compare to dosage compensation by protein degradation? Previous studies showed that 21% of proteins decrease by 1.52-fold [log2 0.6] either due to downregulation of gene expression or protein degradation (Dephoure et al. 2014). To assess what fraction of the proteome is attenuated solely by protein degradation we subtracted protein levels from RNA levels in the data set published by Dephoure et al. (2014). We then pooled data for disome II and disome XII, allowing us to examine 7328 measurements for proteins encoded on euploid chromosomes and 629 measurements for disome II and XII-encoded proteins. As expected, the changes in levels of the 7328 proteins encoded by euploid chromosomes were evenly distributed (Fig. 6D, gray bars). The 629 proteins encoded by disomic chromosomes behaved differently. Both the mean and skew were larger than observed in the expected distribution (Fig. 6D). 209 of the 629 (33.2%) disome-encoded proteins were depleted
by 1.15-fold \(\log_2 0.2\) relative to RNA levels (Fig. 6E); 18.4\% by 1.32-fold \(\log_2 0.4\). Full attenuation, (1.74-fold \(\log_2 0.8\)) occurred for 6.4\% of proteins (Fig. 6E). We conclude that small degrees of attenuation of disome-encoded proteins occurs by both aggregation and degradation. Reduction to levels approaching those seen in euploid cells occurs predominantly through protein degradation.

Finally, we asked whether dosage compensation of a particular protein was mediated by both protein degradation and aggregation, or one or the other in our disome II and XII data set. First, we determined whether a correlation existed between relative abundance of a disome-encoded protein in the total lysate and degree of dosage compensation by aggregation. This was the case, indicating that proteins with higher relative expression levels are more likely to be dosage compensated by aggregation (Fig. 6F). To further assess whether protein aggregation and degradation are mutually exclusive we analyzed the data using cutoffs previously defined (Dephoure et al. 2014). Disome-encoded proteins present in the total lysate at levels below 1.52 \(\log_2 0.6\) (instead of the expected 2 \(\log_2 1\)) were considered dosage compensated by degradation. Disome-encoded proteins that were depleted in the soluble fraction by at least 1.52 \(\log_2 0.6\) compared to the total lysate were considered dosage compensated by aggregation. Based on these criteria, only 9 out of 575 (1.6\%) disomic proteins were dosage compensated by both aggregation and degradation, as evident by the fact that the upper left quadrant in the graph in Fig. 6F is underpopulated \((p= 0.0011; \text{Fisher’s exact test})\). We also asked whether disome-encoded proteins that are dosage compensated by aggregation are present in total lysates at the 2x level expected for disome-encoded proteins. This was the case (Fig. 6G), demonstrating that they are not degraded. In contrast, levels of proteins considered not dosage compensated by aggregation were lower in total extracts. Our data indicate that excess proteins are dosage compensated by aggregation or degradation but rarely both.

**Discussion**

Our analysis of protein aggregation in disomic yeast strains provided insight into why protein aggregation is a universal feature of the aneuploid state and revealed protein aggregation as a means of dosage compensation. This dosage compensation is not only relevant in aneuploid cells but could very well contribute to stoichiometry control in euploid cells that encounter stoichiometric imbalances due to transient imbalances caused by variability in gene expression. Remarkably, aggregation is nearly as effective as protein degradation at lowering levels of excess proteins. Whether protein aggregation serves a cytoprotective role in situations where high levels of unassembled complex subunits are present in cells (i.e. in aneuploid cells) is an important question that remains to be answered.

**Which proteins aggregate in aneuploid cells?**

Our analysis of protein aggregation in a series of disomic yeast strains provided insight into why protein aggregation is a universal feature of the aneuploid state. We identified proteins encoded
on the disomic chromosomes as well as proteins encoded on euploid chromosomes to be enriched in aggregates.

Among the proteins found in aggregates of multiple different aneuploid strains, ribosomes were the most prominent. Ribosomes comprise ~75% of aggregates isolated from both euploid cells and aneuploid cells, but ribosomes aggregate more readily in aneuploid cells as judged by the fact that they harbor more aggregates. Why ribosomes are enriched in aggregates of disomic yeast strains is not clear. Perhaps a higher fraction of ribosomes is defective in disomic yeast strains causing them to aggregate.

Ribosomes were not the only proteins commonly found in aggregates of aneuploid yeast strains. Interestingly, the proteins that aggregated in multiple different aneuploid cell lines also aggregated when protein quality control pathways were impaired. This observation raises the interesting possibility that proteins that are especially dependent on protein quality control pathways to maintain their solubility are “canary in the coal mine” proteins of the state of cellular protein quality control. It will be interesting to determine which properties make the canary proteins so sensitive to perturbations in protein homeostasis.

We also analyzed proteins that aggregate because their encoding genes were duplicated due to disomy. These proteins were strongly enriched for subunits of protein complexes leading us to hypothesize that subunits of heteromeric protein complexes present at levels twice their binding partners are prone to aggregation. We went on to demonstrate that this was true in the case of the eIF2 complex. Our analysis of human trisomic cell lines further revealed that aggregation of proteins that are in excess is surprisingly sensitive to alterations in gene expression. Changing gene expression by as little as 50% causes aggregation of many proteins.

**Cellular response to excess subunits of protein complexes**

Our findings have important implications for euploid cells. Although expression of subunits of the same complex is tightly coordinated in eukaryotes (Li et al. 2014; Taggart and Li 2018), it is likely that even euploid cells encounter transient stoichiometric imbalances. Variability in expression of individual subunits can lead to stoichiometric imbalances where individual subunits lack binding partners or where protein complexes are only partially assembled.

Our study shows that 61.5% of proteins either aggregate or are degraded when produced in excess. Among proteins that function in complexes, 73% of proteins either aggregate or are degraded. Interestingly, the 27% that are neither aggregated nor degraded have significantly smaller heteromeric protein binding interfaces than protein complex subunits that aggregate or are degraded. We propose that excess proteins that neither aggregate nor are degraded are simply less aggregation prone and lack the signals that target them for degradation. Whether there are
features that distinguish proteins that are degraded from proteins that are aggregated remains to be determined.

Our data also indicate that aggregation and degradation of proteins encoded on disomic chromosomes is largely mutually exclusive. Intuitively this makes sense - if excess proteins are degraded there is no excess protein to aggregate. What determines whether excess proteins are degraded or aggregate is their half-life when unbound. This is what we observe for Orc2 and Orc5. Overexpressed Orc2 has a shorter overall half-life, presumably because excess Orc2 is degraded. Orc5 has a longer overall half-life when overexpressed because excess Orc5 aggregates. What was surprising was that a change in protein half-life of two-fold appeared to determine whether an overexpressed protein aggregates or is eliminated by degradation. What determines the half-life of a protein and what minimal half-life is required to be eliminated by degradation when in excess remains to be determined.

**Dosage compensation by protein aggregation**

Our results indicate that protein aggregation is nearly as effective as protein degradation at lowering levels of excess proteins. Using stringent cutoffs to designate a protein being dosage compensated, we found that 12% of disome-encoded proteins were depleted from the soluble fraction by 1.32-fold due to aggregation; depletion by protein degradation occurred for 18.4% of proteins.

We hypothesize that protein aggregation could serve a cytoprotective function that shields aneuploid and euploid cells from toxic activities of excess protein complex subunits. Testing this hypothesis requires the development of methods that prevent protein aggregation in aneuploid cells, a task that has proven difficult. Protein aggregation as a cytoprotective mechanism has been proposed during cellular and organismal aging (David et al. 2010; Walther et al. 2015), suggesting that it could also serve this function in aneuploid cells. However, it is worth noting that the aggregation that occurs during aging does not function to normalize stoichiometric imbalances but rather to protect cells from highly abundant proteins that exceed their solubility during aging. Protein aggregation has also been found to protect cells during stress by sequestering misfolded proteins and targeting them to specific subcellular compartments (Escusa-Toret et al. 2013; Miller et al. 2015). Aggregation of disease inducing proteins such as amyloid β, associated with Alzheimer's Disease, has also been proposed to protect neurons from toxic oligomers (Caughey and Lansbury 2003). Our observation that widespread aggregation serves the purpose of protecting cells from gene dosage excess raises the intriguing possibility that aggregation may be one mechanism that allows cancer cells to tolerate aneuploidy. Analysis of the degree of protein aggregation in cancer cell lines that are highly aneuploid and thus experience large scale stoichiometric imbalances yet have high proliferative potential, could shed light on this question.
Materials and Methods

Yeast strains, plasmids, and growth conditions

All yeast strains are derivatives of W303 and are described in Table S1. Primers are listed in Table S2 and plasmids are listed in Table S3. Yeast strains were generated and manipulated as described previously (Guthrie and Fink 1991). Cells were grown at 30°C in YEP supplemented with 2% raffinose (YEP-R), 2% raffinose + 2% galactose (YEP-RG), or 2% glucose (YEP-D), or in synthetic complete medium supplemented 2% glucose (SC-D). For SILAC experiments, cells were grown overnight in SC-D medium containing 100 µg/mL of heavy (13C6 15N2 (K8), Cambridge Isotope Labs) or light (K4) (Sigma-Aldrich) L-lysine. Cells were then diluted to OD600=0.05 to 0.1 and grown to OD600=0.4 to 1.0 before harvesting lysates. Strains harboring temperature sensitive mutations in NDC10 or RPN6 were grown over night at room temperature, grown to exponential phase at room temperature before shifting to the semi-permissive temperature of 30°C. ndc10-1 strains were grown for 4 hours and rpn6-1 strains were grown for 6 hours at 30°C before harvesting for aggregate purification. For radicicol treatments, cells harboring a deletion in the gene encoding the drug transporter Pdr5 were grown to exponential phase in SC medium at 30°C and radicicol (Cayman Chemical Company) or DMSO was added to the culture at a final concentration of 70 µM. Cells were grown in the presence of radicicol or DMSO for 30 minutes at 30°C before harvesting for aggregate purification.

Disomes used in this study are derivatives of those published in Torres et al. (2007). Gene deletions, fusion proteins, and promoter swaps were generated using PCR-based methods (Longtine et al. 1998) in a wild-type W303 yeast strain. Disomes carrying gene manipulations were constructed by crosses. Karyotypes of key disomic strains were verified by whole genome sequencing.

GCD11-HA and GCD11∆ were generated by PCR based methods (Longtine et al. 1998). GCD11-HA with its native promoter and terminator was cloned into p24 by Gibson cloning (Gibson et al. 2009) and integrated at ura3 by NcoI digestion. The pSUI2/SUI3 CEN plasmid was constructed by Gibson cloning (Gibson et al. 2009) SUI2 and SUI3 with their native promoters and terminators into p158.

Cell culture and SILAC labeling of RPE-1 cells

RPE-1 wild type (control) cells were grown in heavy (K8) SILAC DMEM medium (DMEM with high glucose—minus glutamine, lysine and arginine, supplemented with 10% dialyzed FBS (Gibco), 50µg/mL K8 lysine (Cambridge Isotope Labs), 85µg/mL arginine (Sigma-Aldrich), and 2mM glutamine/1mM sodium pyruvate (Thermo Fisher). RPE-1 cells trisomic for chromosome 12 or 21 were grown in light (K0) SILAC DMEM (same formulation as above, with 50µg/mL K0 lysine; Sigma-Aldrich). Cells were cultured for 8 generations prior to testing K8 labeling efficiency by mass spectrometry, then expanded for harvest at passage 10. Prior to harvest, cells were treated with 25µM chloroquine for 16 hours, followed by addition of 1µM MG-132 (Calbiochem) for 6 hours to induce protein aggregation. Cells were harvested by
trypsinization, neutralized in SILAC DMEM, and washed with PBS; an equal number of heavy and light cells were mixed (wild type + Ts12; wild type + Ts21), treated with sodium azide, and snap frozen for aggregate purification.

Aggregate purification and analysis

Aggregate purification was carried out based on methods published by Koplin et al., (2010), with some modifications to the cell lysis procedure. Cells were grown to exponential phase in SC medium under the conditions indicated above. Sodium azide was added to a final concentration of 50 mM in the cultures before pelleting cells. 10 OD\textsubscript{600} units of cell pellets were washed with 50 mM sodium azide and snap frozen in liquid nitrogen. Frozen pellets were then resuspended in 1 mL of buffer containing 1M sorbitol, 100mM sodium citrate, 60mM EDTA, 10mM DTT, pH 7.0 (SCED), 1mM PMSF, and 2x protease inhibitor tablets (Roche). Cells were pelleted then resuspended in 1 mL of SCED buffer containing 1 mg/mL 20T Zymolyase (MP Biomedicals) and rotated gently for 8 minutes at room temperature. Digested cells were pelleted by spinning at 250xg for 5 minutes at 4°C. Pellets were washed gently in ice-cold SCED buffer containing 1mM PMSF and 2x protease inhibitors. Cells were lysed by resuspending in 1.5 mL of ice-cold lysis buffer containing 20mM NaPi pH 6.8, 10mM DTT, 1mM EDTA, 0.1% Tween 20 (Sigma-Aldrich), 1 mM PMSF, and 5x protease inhibitors and then sonicated for 8 pulses at output level 4, 50% duty cycle. Lysates were cleared by spinning for 2 minutes at 850xg at 4°C yielding the total lysate fraction. Protein concentrations of the cleared lysate were determined by Bradford (Bio-Rad). For quantitative Western blotting and Coomassie staining, samples were diluted to the same protein concentration. A small aliquot of the total lysate fraction was taken for analysis and aggregates were pelleted from the remainder of the total lysate by spinning the extract for 20 minutes at 16,000xg at 4°C. The supernatant was removed and reserved as the soluble fraction. Pellets were then washed twice by resuspending in buffer containing 20mM NaPi pH 6.8, 2% NP40, 1mM PMSF, and 2x protease inhibitors then sonicating for 6 pulses at output level 4, 50% duty cycle. A final wash was carried out in buffer containing 20mM NaPi pH 6.8, 1mM PMSF, and 2x protease inhibitors then sonicating for 4 pulses at output level 2, 60% duty cycle yielding the aggregate fraction. All centrifugations during the wash steps were 20 minutes at 16,000xg at 4°C.

For Western blot analysis and Coomassie staining analysis, total lysate fractions were boiled in SDS loading buffer. Aggregate fractions were resuspended in buffer containing 200mM NaPi pH 6.8, 5% SDS, 8M Urea, 10mM DTT, and 0.01% bromophenol blue (HU buffer) then vortexed at 1500 rpm for 5 minutes at 60°C. For coomassie staining, SDS-PAGE gels were stained with Imperial protein stain (Thermo Scientific) per manufactures instructions. For Western blotting, proteins were separated by SDS-PAGE then transferred to nitrocellulose membranes and detected by the following antibodies. Hsp104-eGFP was detected using a mouse anti-GFP antibody (JL-8 epitope, Clontech) at a dilution of 1:1000. Pgk1 was detected using a mouse anti-Pgk1 antibody (Invitrogen) at a 1:10,000 dilution. Gcd11-HA was detected using a
mouse anti-HA antibody (HA.11 epitope, BioLegend). Quantification was performed using Fiji software (Schindelin et al. 2012).

**Ribosome purification**

Cells were grown to exponential phase, pelleted by centrifugation, washed with water, then snap frozen in liquid nitrogen. Cells were incubated in lysis buffer (20 mM HEPES pH 7.4, 100 mM potassium acetate, 2 mM magnesium acetate, 3 mM DTT, protease inhibitor tablets, and 1 mg/mL Zymolyase) for 5 minutes at 4°C then lysed by French Press (Sim-Aminco). The lysate was cleared by centrifuging for 20 minutes at 19,000 RPM (Beckman Coulter JA25.50 rotor) at 4°C. The cleared lysates were applied to a 30% sucrose gradient containing 20 mM HEPES pH 7.4, 500 mM potassium acetate, 2 mM magnesium acetate, and 3 mM DTT. Ribosomes were pelleted by centrifugation for 4 hours at 4°C at 50,000 RPM (Beckman Coulter Type 70 Ti rotor). The pellet was dissolved in lysis buffer and analyzed by SDS-PAGE.

**Quantitative Proteomics of Yeast Aggregates**

5 OD units of heavy-labeled cells were mixed with 5 OD units of light-labeled cells and aggregates were harvested as described above. Purified SILAC-labeled aggregates were boiled in SDS lysis buffer (50 mM Tris pH 7.5, 2 mM EDTA, 2% SDS) and separated on 4-12% Tris-Glycine by SDS-PAGE gels (Invitrogen). Proteins were visualized by Coomassie staining (45% methanol, 5% glacial acetic acid, 3 g/L Coomassie brilliant blue G-250) and subjected to gel band cutting (Shevchenko et al. 2006), destaining, and in-gel Lys-C (Wako Chemicals) digest at a 50:1 protein to protease ratio to liberate peptides. Following digest, the buffer containing peptides and gel slices were acidified using 50% acetonitrile/5% formic acid, and recovered peptides were vacuum centrifuged to near dryness. Each gel fraction was desalted via StageTip, dried via vacuum centrifugation, and reconstituted in 5% acetonitrile, 5% formic acid for LC-MS/MS processing.

**Quantitative proteomics of RPE-1 cell aggregates**

RPE-1 cells were cultured and treated as described above. Aggregate purification was carried out as described for yeast cells with the following modifications. Cells were collected, treated with sodium azide and snap frozen. Frozen cell pellets were resuspended in cold lysis buffer (described above) and sonicated. Samples were analyzed using the same mass spectrometric method and data processing workflow as yeast aggregates (see below).

**Liquid chromatography and mass spectrometry**

MS data were collected using a Q Exactive mass spectrometer (Thermo Fisher) coupled with a Famos autosampler (LC Packings) and an Accela600 liquid chromatography (LC) pump (Thermo Fisher). Peptides were separated on an ~18 cm column with 100 μm inner diameter packed with of Accucore150 resin (2.6 μm, 150 Å, ThermoFisher Scientific, San Jose, CA); ~1 μg peptides were loaded onto the column for each analysis. Peptides were separated with a
2 hour gradient of 5-26% acetonitrile in 0.125% formic acid with a flow rate of ~300 nL/min. For the MS1 scan, resolution was set to 70,000 with an automatic gain control (AGC) target $1 \times 10^6$ and a maximum injection time of 250 ms. We selected the top 20 precursors for HCD MS2 analysis with the following parameters: resolution, 17,500; AGC $1 \times 10^5$; maximum injection time, 90 ms; isolation window, 2 Th; normalized collision energy (NCE), 25; and centroid spectrum data type. In addition, unassigned and singly charged species were excluded from MS2 analysis, and dynamic exclusion was set to automatic.

For data analysis, mass spectra were processed using a Sequest-based in-house software pipeline. MS spectra were converted to mzXML using a modified version of ReAdW.exe. MS2 spectra were searched with a database including all predictive ORFs for entries from the yeast SGD (http://www.yeastgenome.org/download-data; downloaded March 12, 2014). For human aggregate samples, Database searching included all entries from the human UniProt database (10 August 2011). Both yeast and human databases were concatenated with a reverse database composed of all protein sequences in reverse order. Searches were performed using a 50 ppm precursor ion tolerance. Product ion tolerance was set to 0.03 Th. Oxidation of methionine residues (+15.995 Da) and heavy lysine (K8) incorporation (+8.0142) were set as a variable modification. Peptide spectral matches (PSMs) were altered to a 1% False discovery rate (FDR) (Elias and Gygi 2007; 2010). PSM filtering was performed using a linear discriminant analysis, as described previously (Huttlin et al. 2010), while considering the following parameters: XCorr, ΔCn, missed cleavages, peptide length, charge state, and precursor mass accuracy. Peptide-spectral matches were identified, quantified, and collapsed to a 1% FDR and then further collapsed to a final protein-level FDR of 1%. Furthermore, protein assembly was guided by principles of parsimony to produce the smallest set of proteins necessary to account for all observed peptides. 4 gel band regions were cut per sample (individual lanes) of the SDS-PAGE gel; these 4 regions were processed separately and each is an independent MS sample (to decrease complexity of peptides in each run). Protein assembly was utilized to group the 4 runs of a given sample together for batched analysis and calculation of $\log_2$(Heavy/Light) ratios. The resulting data were filtered for SILAC quantified proteins based on the summed signal to noise for heavy and light peptides; contaminant peptides identified in the search were removed at this step. An intensity cutoff of 10 was applied for summed heavy plus light channels, and each individual channel had an intensity cutoff of 5 (to avoid identifying proteins with an intensity of 0 in either the light or heavy channel; i.e. proteins found only in one condition or the other). A SILAC-labeled total lysate reference sample (to allow for normalization of SILAC mixing) was obtained as described above. Proteins were pelleted by TCA precipitation, dried via vacuum centrifugation, and digested with Lys-C. Resulting peptides were desalted using StageTips, and MS data collection and analysis were performed as described above for aggregate samples.

**SILAC mass spectrometry of total lysate and soluble fractions**

Total lysate samples were prepared, and soluble fractions (supernatant post aggregate isolation) were collected as described above. ~800 µg of protein per sample was pelleted via TCA
precipitation and dried via vacuum centrifugation. Samples were reduced and alkylated followed by digestion with Lys-C. Resulting peptides were desalted using StageTips and samples were dried via vacuum centrifugation.

Each sample was fractionated using off-line basic pH reversed-phase chromatography (BPRP HPLC) (Wang et al. 2011). We used an Agilent 1200 pump equipped with a degasser and a photodiode array (PDA) detector (set at 220 and 280 nm wavelength) from ThermoFisher Scientific. Peptides were subjected to a 50-min linear gradient from 5% to 35% acetonitrile in 10 mM ammonium bicarbonate pH 8 at a flow rate of 0.6 mL/min over an Agilent 300Extend C18 column (3.5 μm particles, 4.6 mm ID and 220 mm in length). The peptide mixture was fractionated into a total of 96 fractions, which were consolidated into 24, from which 12 non-adjacent samples were analyzed (Paulo et al. 2016). Samples were subsequently acidified with 1% formic acid and vacuum centrifuged to near dryness. Each consolidated fraction was desalted via StageTip, dried again via vacuum centrifugation, and reconstituted in 5% acetonitrile, 5% formic acid for LC-MS/MS processing. Samples were analyzed using a Q Exactive mass spectrometer using the same instrument method and data processing as described above for yeast aggregate samples.

**Real-time RT-qPCR**

Cells were grown to exponential phase in SC medium containing 2% glucose as for aggregate purification. 5 OD₆₀₀ units of culture were pelleted by centrifugation at 4°C (3000 rpm, 2 min). The pellet was resuspended in 1 ml cold SC medium, transferred to a 2 ml microfuge tube and pelleted by centrifugation at 4°C (3000 rpm, 2 min). The pellet was flash-frozen in liquid nitrogen and stored at -80°C. To extract total RNA, ~200 μl of glass beads, 400 μl TES buffer (10 mM Tris pH 7.5, 10 mM EDTA, 0.5% SDS) and 400 μl acid phenol:chloroform (pH 4.5) were added to the cell pellet and the tubes were vortexed for 30 minutes at 65°C. The phases were separated by centrifugation, and the top phase was transferred to a new tube containing 1 ml of 120 mM sodium acetate in ethanol to precipitate RNA at 4°C. Precipitates were collected by centrifugation and resuspended in 100 μl DEPC-treated water. Total RNA was further purified using the RNeasy Mini kit (Qiagen), including DNase treatment, according to the manufacturer’s instructions. cDNA was synthesized from 750 ng total RNA using the SuperScript III First-Strand Synthesis SuperMix kit (Invitrogen) with random hexamer primers according to the manufacturer’s instructions. Real-time qPCR reactions were run using the SYBR Premix Ex Taq Perfect Real Time kit (TaKaRa Bio) and a Roche LightCycler 480 (Roche) according to manufacturer’s instructions. qPCR primers are listed in Table S2.

**Turnover measurements for aggregated proteins**

Protein turnover for aggregated proteins in disome II cells was determined by examining protein levels relative to WT before treatment with MG-132 and chloroquine, and 90 seconds and 300 seconds thereafter. Data were generated by Dephoure et al. (2014).
Orc protein half-life measurements

Cells were grown to exponential phase at 30°C in YEP medium containing 2% raffinose. Expression of HA tagged ORC2 and ORC5 was induced by diluting cultures into YEP medium containing 2% raffinose and 2% galactose for 20 minutes. The 0 minute time point was taken and protein synthesis was halted by the addition of 2% glucose and 0.5 mg/mL cycloheximide (Sigma-Aldrich). Time points were taken at the indicated times after the addition of glucose and cycloheximide. For each time point, approximately 0.5 OD₆₀₀ units of culture were pelleted by centrifugation at 4°C (3000 rpm, 2 min). Cells were incubated at 4°C in 5% trichloroacetic acid for at least 10 minutes. Cell pellets were washed once with acetone and dried. Cells were lysed with glass beads in 100 μL of lysis buffer (50 mM Tris-Cl at pH 7.5, 1 mM EDTA, 2.75 mM dithiothreitol [DTT], complete protease inhibitor cocktail [Roche]) with a bead beater. Samples were boiled in 1X SDS loading buffer. Following SDS-PAGE and transfer of proteins to a nitrocellulose membrane, proteins were detected with the following antibodies. Pgk1 was detected using a mouse anti-Pgk1 antibody (Invitrogen) at a 1:10,000 dilution. Orc2-HA and Orc5-HA were detected using a mouse anti-HA antibody (HA.11 epitope, BioLegend).

Quantification was performed using Fiji software (Schindelin et al. 2012). Protein levels were calculated by subtracting a background measurement for each band then dividing the intensity of the Orc band by the intensity of the Pgk1 band and normalizing all time points to the 0 minute time point. Half-life calculations were made by fitting curves to an exponential decay function in Prism (Graphpad).

SILAC ms data normalization

To account for imperfect mixing of heavy and light-labeled cells, log2 ratios of proteins identified in aggregates were normalized by subtracting the average log2 ratio of all euploid encoded proteins in the total lysate obtained before pelleting aggregates for each experiment.

To control for non-biological batch effects between disomic cell-lines, each experiment was mean-centered to 0 by subtracting the mean of all SILAC ratios in that experiment from all data points. To return the normalized values to a baseline that more closely resembles the increase in protein aggregation in disomic strains observed in the raw data, a constant (log2 0.27) was added to all normalized data points. This constant is the mean log2 ratio of all euploid encoded proteins in the dataset prior to normalization.

Cutoff determination for aggregation

To decide what level of enrichment in disome aggregates constituted calling a protein aggregated, we used a 5% false discovery rate (FDR) obtained from the analysis of aggregates obtained from a WT(heavy)-WT(light) SILAC ms analysis. In this analysis, only 5% of identified proteins were enriched by greater than log2 1.27 in WT(heavy) aggregates.

Signal to noise quantification of relative aggregate burden
To account for the fact that some proteins are more abundant in aggregates than others, aggregate burden for each disome relative to WT was calculated by comparing the signal to noise ratio (S:N) of all heavy-labeled proteins to the S:N of all light-labeled proteins in protein aggregates. The sum of all light-labeled S:N was divided by the sum of all heavy-labeled S:N. This ratio was then normalized by dividing the ratio of light S:N to the heavy S:N for the total lysate.

**Gene Ontology (GO) analysis**

GO component analysis was performed using the Saccharomyces Genome Database (SGD) GO term finder (accessed 10/12/2018).

**Aggregate property calculations**

Disorder predictions for protein sequences were calculated using IUPRED on the ‘long’ setting. For each sequence, per-residue disorder scores were averaged across the full length of the protein. Grand average hydropathy (GRAVY) scores, isoelectric points, aliphatic indices, and aromaticity scores were calculated using the YeastMine tool on Saccharomyces Genome Database (SGD) (accessed 10/31/2018).

**Proteins not quantified due to low signal in WT channel**

In our mass spectrometry analysis pipeline, peptides for which either individual analysis channel had an intensity of less than 5 were discarded to avoid identifying proteins with an intensity of 0 in either the light or heavy channel; i.e. proteins found only in one condition or the other because a SILAC ratio cannot be calculated. We examined proteins that failed to pass the signal to noise threshold in one channel, but had a signal to noise ratio (S:N) of at least twice the threshold in the other channel. Using this method, we found 320 proteins that were quantified only in the disome channel compared to 72 quantified in only the WT channel (Supplemental Data S1). Importantly, 92 of the proteins quantified only in the disome channel were encoded by the duplicated chromosome as opposed to just 2 duplicated gene-encoded proteins quantified in only the WT channel. It is possible that proteins that are identified exclusively in the disome channel never aggregate in WT cells. It is also possible that with increased coverage these proteins would pass the signal threshold in both channels. To distinguish between these possibilities, we took advantage of a difference in coverage between two of our replicate experiments for disome II. In the low coverage experiment (366 proteins quantified), 9 proteins were not quantified due to low signal in the WT channel. In the high coverage experiment (847 proteins quantified), we identified 6 of these proteins, and all 6 passed the detection threshold in both channels allowing us to calculate a SILAC ratio. 4 of these 6 proteins were considered aggregating using 2.4-fold [log2 of 1.27] as a cutoff. We conclude that proteins that cannot be quantified by SILAC ms due to low signal in WT cells are also likely enriched in aneuploid aggregates.
Heteromeric interface size determination

We searched for subunits of heteromeric protein complexes in the Protein Data Bank (on February 2, 2017) with >90% sequence identity to *S. cerevisiae* genes. We selected a single heteromeric structure for each gene – for genes with multiple structures available, we selected the structure with the greatest number of unique subunits in the complex, followed by the greatest number of atoms present in the polypeptide chain for ties. The total amount of heteromeric interface formed by each subunit was calculated using AREAIMOL (Winn et al. 2011).

Statistical analysis

The statistical tests used are indicated in the Figure Legend, Materials and Methods, and/or in the Results section. Values of n, definition of center, error bars (e.g. SD and confidence intervals), and significance levels are reported in the Figures and/or in the Figure Legends. All box plots represent median and interquartile range (IQR) with whiskers indicating the 10-90 percentile. All indicated statistical tests were performed using MATLAB or Prism.

Data availability

The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE (Vizcaíno et al. 2016) partner repository in seven parts with the following dataset identifiers: PXD011874, PXD011875, PXD011876, PXD011877, PXD011878, PXD011915, and PXD011916.

Acknowledgments:

We thank Arzu Sandikci for providing purified ribosomes, Steve Bell for assistance with ORC experiments, David Pincus, Luke Berchowitz, and members of the Amon lab for suggestions and critical reading of this manuscript. This work was supported by NIH grants CA206157 and GM118066 to A.A., who is an investigator of the Howard Hughes Medical Institute and the Paul F. Glenn Center for Biology of Aging Research at MIT. J.A.M. is supported by a Medical Research Council Career Development Award (MR/M02122X/1). S. S. was supported by the American Italian Cancer Foundation (AICF), by a Fellowship in Cancer Research from Marie Curie Actions and the Italian Association for Cancer Research (AIRC), and by a KI Quinquennial Cancer Research Fellowship.

Author contributions:

C.M.B., L.P.V., J.N.W., S.S., J.A.P., Z.S., J.W.H, J.A.M, and A.A. designed the experiments. C.M.B., L.P.V., J.N.W., S.S., J.A.P., J.A.M, and A.A. performed experiments and analyzed results. C.M.B., L.P.V., J.N.W., J.A.M, and A.A. wrote the manuscript. All authors read and approved the final manuscript.
References:

Banani SF, Lee HO, Hyman AA, Rosen MK. 2017. Biomolecular condensates: organizers of cellular biochemistry. *Nature Publishing Group* 18: 285–298.

Bell SP, Kobayashi R, Stillman B. 1993. Yeast origin recognition complex functions in transcription silencing and DNA replication. *Science* 262: 1844–1849.

Caughey B, Lansbury PT. 2003. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. *Annu Rev Neurosci* 26: 267–298.

David DC, Ollikainen N, Trinidad JC, Cary MP, Burlingame AL, Kenyon C. 2010. Widespread protein aggregation as an inherent part of aging in C. elegans. *PLoS Biol* 8: e1000450.

Dephoure N, Hwang S, O'Sullivan C, Dodgson SE, Gygi SP, Amon A, Torres EM. 2014. Quantitative proteomic analysis reveals posttranslational responses to aneuploidy in yeast. *Elife* 3: e03023.

Donnelly N, Storchová Z. 2014. Dynamic karyotype, dynamic proteome: buffering the effects of aneuploidy. *Biochim Biophys Acta* 1843: 473–481.

Elias JE, Gygi SP. 2007. Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry. *Nature Methods* 4: 207–214.

Elias JE, Gygi SP. 2010. Target-decoy search strategy for mass spectrometry-based proteomics. *Methods Mol Biol* 604: 55–71.

Escusa-Toret S, Vonk WIM, Frydman J. 2013. Spatial sequestration of misfolded proteins by a dynamic chaperone pathway enhances cellular fitness during stress. *Nat Cell Biol* 15: 1231–1243.

Gibson DG, Young L, Chuang R-Y, Venter JC, Hutchison CA, Smith HO. 2009. Enzymatic assembly of DNA molecules up to several hundred kilobases. *Nature Methods* 6: 343–345.

Gonçalves E, Fragoulis A, Garcia-Alonso L, Cramer T, Saez-Rodriguez J, Beltrao P. 2017. Widespread Post-transcriptional Attenuation of Genomic Copy-Number Variation in Cancer. *Cell Syst* 5: 386–398.e4.

Guthrie C, Fink GR. 1991. *Methods in enzymology: molecular biology of Saccharomyces cerevisiae*. Academic Press, San Diego.

Huttlin EL, Jedrychowski MP, Elias JE, Goswami T, Rad R, Beausoleil SA, Villén J, Haas W, Sowa ME, Gygi SP. 2010. A tissue-specific atlas of mouse protein phosphorylation and expression. *Cell* 143: 1174–1189.
Isono E, Saito N, Kamata N, Saeki Y, Toh-E A. 2005. Functional analysis of Rpn6p, a lid component of the 26 S proteasome, using temperature-sensitive rpn6 mutants of the yeast Saccharomyces cerevisiae. *J Biol Chem* **280**: 6537–6547.

Jain S, Wheeler JR, Walters RW, Agrawal A, Barsic A, Parker R. 2016. ATPase-Modulated Stress Granules Contain a Diverse Proteome and Substructure. *Cell* **164**: 487–498.

Koplin A, Preissler S, Ilina Y, Koch M, Scior A, Erhardt M, Deuerling E. 2010. A dual function for chaperones SSB-RAC and the NAC nascent polypeptide-associated complex on ribosomes. *J Cell Biol* **189**: 57–68.

Levy ED, De S, Teichmann SA. 2012. Cellular crowding imposes global constraints on the chemistry and evolution of proteomes. *Proc Natl Acad Sci USA* **109**: 20461–20466.

Li G-W, Burkhardt D, Gross C, Weissman JS. 2014. Quantifying Absolute Protein Synthesis Rates Reveals Principles Underlying Allocation of Cellular Resources. *Cell* **157**: 624–635.

Liu B, Larsson L, Caballero A, Hao X, Oling D, Grantham J, Nyström T. 2010. The polarisome is required for segregation and retrograde transport of protein aggregates. *Cell* **140**: 257–267.

Longtine MS, McKenzie A, Demarini DJ, Shah NG, Wach A, Brachat A, Filippsen P, Pringle JR. 1998. Additional modules for versatile and economical PCR-based gene deletion and modification in *Saccharomyces cerevisiae*. *Yeast* **14**: 953–961.

Marsh JA, Hernández H, Hall Z, Ahnert SE, Perica T, Robinson CV, Teichmann SA. 2013. Protein Complexes Are under Evolutionary Selection to Assemble via Ordered Pathways. *Cell* **153**: 461–470.

McShane E, Sin C, Zauber H, Wells JN, Donnelly N, Wang X, Hou J, Chen W, Storchová Z, Marsh JA, et al. 2016. Kinetic Analysis of Protein Stability Reveals Age-Dependent Degradation. *Cell* **167**: 803–815.e21.

Miller SBM, Mogk A, Bukau B. 2015. Spatially Organized Aggregation of Misfolded Proteins as Cellular Stress Defense Strategy. *Journal of Molecular Biology* 1–11.

Ong S-E, Blagoev B, Kratchmarova I, Kristensen DB, Steen H, Pandey A, Mann M. 2002. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. *Mol Cell Proteomics* **1**: 376–386.

Ori A, Iskar M, Buczak K, Kastritis P, Parca L, Andrés-Pons A, Singer S, Bork P, Beck M. 2016. Spatiotemporal variation of mammalian protein complex stoichiometries. *Genome Biol* **17**: 47.

Oromendia AB, Dodgson SE, Amon A. 2012. Aneuploidy causes proteotoxic stress in yeast. *Genes & Development* **26**: 2696–2708.
Paulo JA, O'Connell JD, Everley RA, O'Brien J, Gygi MA, Gygi SP. 2016. Quantitative mass spectrometry-based multiplexing compares the abundance of 5000 S. cerevisiae proteins across 10 carbon sources. *J Proteomics* **148**: 85–93.

Pavelka N, Rancati G, Zhu J, Bradford WD, Saraf A, Florens L, Sanderson BW, Hattem GL, Li R. 2010. Aneuploidy confers quantitative proteome changes and phenotypic variation in budding yeast. *Nature* **468**: 321–325.

Pu S, Wong J, Turner B, Cho E, Wodak SJ. 2009. Up-to-date catalogues of yeast protein complexes. *Nucleic Acids Res* **37**: 825–831.

Rachidi M, Lopes C, Costantine M, Delabar J-M. 2005. C21orf5, a new member of Dopey family involved in morphogenesis, could participate in neurological alterations and mental retardation in Down syndrome. *DNA Res* **12**: 203–210.

Santaguida S, Amon A. 2015. Short- and long-term effects of chromosome mis-segregation and aneuploidy. *Nature Publishing Group* **16**: 473–485.

Santaguida S, Vasile E, White E, Amon A. 2015. Aneuploidy-induced cellular stresses limit autophagic degradation. *Genes & Development* **29**: 2010–2021.

Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, et al. 2012. Fiji: an open-source platform for biological-image analysis. *Nature Methods* **9**: 676–682.

Shevchenko A, Tomas H, Havlis J, Olsen JV, Mann M. 2006. In-gel digestion for mass spectrometric characterization of proteins and proteomes. *Nat Protoc* **1**: 2856–2860.

Stingele S, Stoehr G, Peplowska K, Cox J, Mann M, Storchová Z. 2012. Global analysis of genome, transcriptome and proteome reveals the response to aneuploidy in human cells. *Molecular Systems Biology* **8**: 608.

Taggart JC, Li G-W. 2018. Production of Protein-Complex Components Is Stoichiometric and Lacks General Feedback Regulation in Eukaryotes. *Cell Syst* **7**: 580–589.e4.

Tang Y-C, Williams BR, Siegel JJ, Amon A. 2011. Identification of Aneuploidy-Selective Antiproliferation Compounds. *Cell* **144**: 499–512.

Torres EM, Dephoure N, Panneerselvam A, Tucker CM, Whittaker CA, Gygi SP, Dunham MJ, Amon A. 2010. Identification of aneuploidy-tolerating mutations. *Cell* **143**: 71–83.

Torres EM, Sokolsky T, Tucker CM, Chan LY, Boselli M, Dunham MJ, Amon A. 2007. Effects of aneuploidy on cellular physiology and cell division in haploid yeast. *Science* **317**: 916–924.

Vizcaíno JA, Csordas A, del-Toro N, Dianes JA, Griss J, Lavidas I, Mayer G, Perez-Riverol Y, Reisinger F, Ternent T, et al. 2016. 2016 update of the PRIDE database and its related tools. *Nucleic Acids Res* **44**: D447–56.
Walther DM, Kasturi P, Zheng M, Pinkert S, Vecchi G, Ciryam P, Morimoto RI, Dobson CM, Vendruscolo M, Mann M, et al. 2015. Widespread Proteome Remodeling and Aggregation in Aging C. elegans. Cell 161: 919–932.

Wang Y, Yang F, Gritsenko MA, Wang Y, Clauss T, Liu T, Shen Y, Monroe ME, Lopez-Ferrer D, Reno T, et al. 2011. Reversed-phase chromatography with multiple fraction concatenation strategy for proteome profiling of human MCF10A cells. Proteomics 11: 2019–2026.

Winn MD, Ballard CC, Cowtan KD, Dodson EJ, Emsley P, Evans PR, Keegan RM, Krissinel EB, Leslie AGW, McCoy A, et al. 2011. Overview of the CCP4 suite and current developments. Acta Crystallogr D Biol Crystallogr 67: 235–242.
Figure 1. Identification of proteins that aggregate in aneuploid yeast cells.

(A) Total lysate, aggregates and soluble fractions obtained from exponentially growing cells expressing Hsp104-eGFP (A31392) were analyzed for Hsp104 and Pgk1 abundance.

(B) Protein aggregates and total lysates were prepared from euploid cells (WT, A35797), ndc10-1 (ndc10-1, A13413) cells grown at 30°C for 4 hours, disome V cells (Dis V, A28265), and euploid (A2587) cells after an 8 minute heat shock at 42°C (heat shock). Total lysates and aggregate fractions were subjected to SDS-PAGE and stained with coomassie.

(C) WT and disome cells were grown to exponential phase in SC medium containing heavy lysine and light lysine, respectively. Aggregated proteins are separated into two dot plots with red dots indicating proteins encoded on the duplicated chromosome and gray dots indicating proteins encoded on euploid chromosomes. The first column represents aggregates purified from a mixed sample of heavy lysine-labeled WT and light lysine-labeled WT. Lines represent mean and standard deviation. Upper dashed line at log2 1.27 shows the cut-off used to define aggregating proteins. ** p < 0.01, **** p < 0.0001; Mann-Whitney test.

(D) The average aggregate enrichment of proteins encoded on euploid chromosomes that were identified in aggregates of at least 3/12 disomes. Only proteins with an average enrichment of >log2 1.27 as measured in Fig. 1C are shown. Error bars indicate standard deviation.

(E) The enrichment of proteins from (D) was compared to their enrichment in aggregates purified from cells treated with radicicol (orange) or cells harboring the rpn6-1 allele (purple) from (Supplemental Fig. S4). * indicates proteins that were not quantified in either the radicicol or rpn6-1 experiments because they did not pass the detection threshold in aggregates purified from the reference strain but were readily detected in aggregates isolated from radicicol treated or rpn6-1 cells.

(F) The percentage of proteins encoded by the duplicated chromosome that were enriched at a level greater than the aggregation threshold of log2 1.27 (black bars) and the percentage of proteins encoded by the duplicated chromosome as a fraction of the whole proteome (gray bars). n.s. not significant, **** p<0.0001; cumulative distribution function (CDF) for a hypergeometric distribution.

(G) The percentage of proteins encoded by the duplicated chromosome that were not quantified by SILAC ms because the heavy-labeled (WT) peptides did not pass the detection threshold (black bars) and the percentage of proteins encoded by the duplicated chromosome as a fraction of the whole proteome (gray bars). n.s. not significant, ** p<0.01, *** p<0.001, **** p<0.0001; CDF for a hypergeometric distribution.

Abbreviations: WT, wild-type; Dis, disome; avg, average.
Figure 2. Aggregate analysis in trisomic human cells.
(A) RPE-1 cells and RPE-1 cells trisomic for either chromosome 12 or chromosome 21 were cultured in medium containing heavy lysine or light lysine, respectively, for 10 generations. Within each experiment, euploid encoded proteins (gray dots) were plotted separately from trisome encoded proteins (red dots). **** p<0.0001, n.s. not significant; Mann-Whitney test.
(B, C) Enrichment of chromosome 12 (B) and 21 (C) encoded proteins in total aggregates (gray bars) and among the top 10% most highly enriched aggregated proteins (black bars). n.s. not significant, **** p<0.0001; cumulative distribution function (CDF) for a hypergeometric distribution.
(D) Euploid and trisomy 21 cells were treated with 25nM chloroquine and 1µM MG-132 and aggregates were plotted as in (A), *** p<0.001; Mann-Whitney test.
(E) Enrichment of chromosome 21 encoded proteins in total aggregates (gray bar) and among the top 10% most highly enriched aggregated proteins (black bar). **** p<0.0001; CDF for a hypergeometric distribution.
Abbreviations: WT, wild-type; Ts, trisome; Chr, chromosome.
Figure 3. Stoichiometric imbalances of protein complex subunits cause protein aggregation.  
(A) The percentage of proteins encoded by duplicated chromosomes enriched by \( \log_2 1.27 \) or more in aggregates (red), the percentage of proteins encoded by euploid chromosomes enriched by a \( \log_2 1.27 \) or more in aggregates (gray), and the percentage of proteins in the genome (black) that are annotated to form protein complexes by Pu et al. (2009) was calculated. **** indicates \( p < 0.0001 \), n.s. not significant; cumulative distribution function (CDF) for a binomial distribution.  
(B) Diagram of eIF2 complex stoichiometry in disome V cells.  
(C) Gcd11-HA in aggregates and total lysates in WT, (A40189), disome V (A40190), disome V GCD11-HA/gcd11\( \Delta \) (A40191), and WT \( \text{URA3::GCD11-HA} \) (WT +\( \text{GCD11} \); A40192) cells. Only one of the two GCD11 genes in disome V cells was tagged with HA to ensure that protein levels are comparable between strains.  
(D) Quantification of Western blots in (C) (n=3; SD; *** indicates \( p < 0.001 \), T test)  
(E) Cells were grown as in (C) and mRNA levels for eIF2 subunits was determined. Values were normalized to \( \text{ACT1} \) then to WT expression levels (n=3; SD).  
(F-H) Western blot, relative aggregation quantification, and mRNA expression was determined for WT (A40193), disome V (A40194), and disome V p\( \text{SUI2/SUI3} \) (A40195) cells as described in (C-E; n=3; SD; ** indicates \( p < 0.01 \), T test)  
Abbreviations: WT, wild-type; Dis, disome; rel, relative.
**Figure 4. Excess proteins are either aggregated or degraded.**

(A, B) Correlation between enrichment in protein aggregates (measured in Fig. 1C) and relative protein levels (measured in disome lysates by Dephoure et al. (2014)) was determined for all proteins encoded by the duplicated chromosome quantified in both data sets (A), and duplicated subunits of protein complexes (B). Spearman correlation of 0.1810 (p=1.2x10^{-8}) in (A) and 0.2814 (p< 0.0001) in (B). Dashed lines indicate thresholds for proteins being considered aggregated (y-axes) or degraded (x-axes). The number of proteins that fall into each quadrant is indicated.

(C, D) All duplicated proteins (C) and duplicated complex subunits (D) were separated into two bins: (1) aggregated proteins (red bars), which were defined as proteins with an enrichment of at least log2 1.27 in disomic aggregates; (2) non-aggregated proteins (gray bars) which were defined as proteins with an enrichment of log2 0.727 or less. Average relative levels in disome lysates as measured by Dephoure et al. (2014) are plotted. Error bars represent 95% confidence intervals. **** indicates p< 0.0001, Mann-Whitney test.

Abbreviations: WT, wild-type; Dis, disome
Figure 5. Protein half-life determines whether a protein aggregates or is degraded.

(A) Proteins encoded on duplicated chromosomes were separated into three categories: aggregated, degraded, and neither. Aggregated proteins (red), degraded proteins (blue) were defined as in Fig. 4A. Proteins that were identified in our analysis and that by Dephoure et al. (2014) but did not pass the threshold for aggregation or degradation were considered neither aggregated nor degraded (gray). The heteromeric interface sizes of the proteins in each category are plotted as box plots with whiskers representing the 10th-90th percentile. **** p< 0.0001, ** p< 0.01, n.s. not significant; Mann-Whitney test.

(B) The change in levels of proteins encoded on chromosome II in disome II in total lysates of cells treated with 100 µM MG-132 and 10 mM chloroquine relative to WT (data from Dephoure et al. (2014)). Examples of aggregating proteins as determined in Fig. 1C and of degraded proteins as determined by Dephoure et al. (2014) are shown. White bars indicate relative levels immediately before the addition of MG-132 and chloroquine, gray bars and black bars relative levels 90 seconds and 300 seconds thereafter, respectively.

(C) Mean levels of all aggregating proteins as measured in (B) at each time point (error bars SEM; n.s. not significant; Wilcoxon matched-pairs signed rank test).

(D) Disome II rpn6-1 (A40196) or WT (A23504) cells were grown to exponential phase at 30°C in SC medium containing light lysine and heavy lysine respectively and aggregating proteins were identified. Lines indicate mean and standard deviation. **** p < 0.0001, Mann-Whitney test.

(E) Proteins considered degraded when duplicated by Dephoure et al. (2014) were examined in aggregates purified from disome II cells (Fig. 1C) and from disome II rpn6-1 cells (D). A protein was considered to aggregate when it was enriched by more than log2 1.27 in aggregates (red), not aggregated as enriched by less than log2 1.27 (gray). no ID indicates proteins that were not identified in aggregates (white). ** p < 0.01, cumulative distribution function for a binomial distribution.

(F) Degree of aggregation was determined for all proteins in (E) in disome II aggregates and disome II rpn6-1 aggregates. Bars represent SD; ** p<0.01, Mann-Whitney test.

(G, H) Relative protein levels as determined by Dephoure et al. (2014) (G) and relative aggregation as measured in Fig. 1C (H) for ORC subunits when encoded by disomic chromosomes (n.d. - not detected in aggregates).

(I, J) Cells were grown to exponential phase at 30°C in YEP medium containing 2% raffinose. Expression of HA tagged ORC2 (A40197) and ORC5 (A40198) was induced with 2% galactose for 20 minutes. Then protein synthesis was halted by the addition of 2% glucose and 0.5 mg/mL cycloheximide (t=0). Protein levels were determined. Pgk1 was used as a loading control (I). Protein levels were quantified relative to the loading control and normalized to the 0 minute time point (J).

Abbreviations: WT, wild-type; Dis, disome; MG, MG-132; CQ, chloroquine; sec, second; ln, natural logarithm; ID, identification; mins, minutes.
Figure 6. Dosage compensation by protein aggregation.
(A, B) Total lysate and soluble fractions, obtained as described in Fig. 1A, were analyzed for disome II (A) and disome XII (B). Proteins encoded by euploid chromosomes (gray), proteins encoded by the duplicated chromosome (red). Data are represented as box plots with whiskers extending to 10th and 90th percentiles. Means are indicated below. Upper dashed line represents the theoretical mean for proteins encoded by the duplicated chromosome. **** p<0.0001; Mann-Whitney test.

(C) Changes in protein levels due to aggregation for proteins quantified in (A, B) were calculated for every protein by subtracting its log2 ratio in the soluble fraction from its log2 ratio in the total lysate. Disome II and disome XII data were pooled and separated into two subsets: euploid chromosome encoded proteins (gray) and disomic chromosome encoded proteins (red). Frequency distributions of each subset were then generated using a bin size of 0.1. Distributions were fit to Gaussian curves for euploid (dashed line) and disomic (solid line). p-value shows that mean change of disome encoded proteins is significantly different from the mean change of euploid encoded proteins (Mann-Whitney test).

(D) Changes in protein levels due to degradation for disome II and disome XII were calculated by subtracting the relative protein level from the relative mRNA level for each gene as measured by Dephoure et al. (2014). Frequency distributions were generated and curve fitting was performed on the pooled data as in (C). p-value shows that mean change of disome encoded proteins is significantly different from the mean change of euploid encoded proteins (Mann-Whitney test).

(E) The percentage of proteins encoded by the duplicated chromosome that decreased in levels by at least a log2 of 0.2, 0.4, 0.6, and 0.8 due to aggregation (red bars) was calculated using the data described in (C) and due to degradation (blue bars) using the data in (D). **** p<0.0001, ** p<0.01, * p<0.05; Chi-squared test.

(F) Correlation between protein levels in total lysate and reduction in levels due to aggregation was determined for proteins encoded on duplicated chromosomes from the pooled data set of disome II (A) and disome XII (B). Spearman correlation of 0.3589 (p< 0.0001). Dashed lines indicate thresholds for proteins being considered dosage compensated by aggregation (y-axes) or degradation (x-axes). The number of proteins that fall into each quadrant is indicated (note: 19 data points fell outside the range of the axes but were included in the calculations).

(G) Proteins encoded on duplicated chromosomes were separated into two categories: dosage compensated proteins (red) were defined as their levels being reduced by at least log2 0.4 in the soluble fraction relative to the total lysate. Not dosage compensated proteins (gray) were defined as their levels being reduced by less than log2 0.4. Mean levels in total lysates are plotted; error bars indicate 95% confidence intervals. **** p<0.0001; Mann-Whitney test.

Abbreviations: WT, wild-type; Dis, disome.